Table 2.
FVIII activity and CWA-TT.
| FVIII Activity |
FFH of CWA-TT (mm Absorbance) |
FFT of CWA-TT (Second) |
1st DPH of CWA-TT (mm Absorbance) |
1st DPT of CWA-TT (Second) |
||||
|---|---|---|---|---|---|---|---|---|
| Emi (+) | Emi (−) | Emi (+) | Emi (−) | Emi (+) | Emi (−) | Emi (+) | Emi (−) | |
| 100% | 481 ± 6.88 | 434 ± 8.30 | 186 ± 3.37 | 184 ± 1.56 | 52.7 ± 1.47 | 53.7 ± 1.56 | 33.3 ± 1.26 | 32.5 ± 1.52 |
| 30% | 435 ± 5.46 | 433 ± 1.96 | 131 ± 6.57 | 127 ± 6.44 | 50.6 ± 2.85 | 49.4 ± 3.74 | 37.8 ± 2.05 | 35.4 ± 6.30 |
| 10% | 370 ± 4.00 | 371 ± 4.55 | 93.3 ± 4.47 | 90.6 ± 2.43 | 50.8 ± 1.34 | 49.3 ± 2.29 | 33.8 ± 0.91 | 33.6 ± 1.22 |
| 3% | 347 ± 2.71 | 347 ± 4.46 | 80.1 ± 3.02 | 81.2 ± 3.35 | 46.3 ± 3.82 | 47.2 ± 4.63 | 31.1 ± 2.42 | 30.7 ± 1.36 |
| 1% | 330 ± 2.91 | 331 ± 2.69 | 73.6 ± 2.04 | 74.8 ± 5.25 | 44.8 ± 2.86 | 46.4 ± 3.62 | 33.4 ± 1.30 | 33.5 ± 0.86 |
Data are shown as the mean ± standard deviation. FFH, fibrin formation curve height; FFT, fibrin formation curve time; 1st DPH, first derivative peak height; 1st DPT, first derivative peak time; Emi (+), with emicizumab; Emi (−), without emicizumab. All assays were performed more than three times to confirm the reproducibility.